Percheron Therapeutics Limited has released a press release.
Long COVID-19 strategic collaboration with US Experts
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Dosing commenced in MCRI collaboration animal study
- Quarterly Report and Appendix 4C
- Entitlement Offer Results
- Annual General Meeting Presentation
- Positive UK PIP Decision & PDCO opinion ratification by EMA
Later from Percheron Therapeutics
- Bonus Option Offer
- Prospectus
- New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
- ATL1102 DMD Clinical Trial Application Submitted in Europe
- Voluntary Suspension
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics